Theratechnologies ROCE
What is the ROCE of Theratechnologies?
The ROCE of Theratechnologies, Inc. is 0.00%
What is the definition of ROCE?
Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used.
= EBIT / (assets - current liabilities)
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE of companies in the Health Care sector on TSX compared to Theratechnologies
What does Theratechnologies do?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Companies with roce similar to Theratechnologies
- Omega Alpha Spac has ROCE of -0.01%
- The Gap has ROCE of -0.01%
- Elemental Royalties Ltd has ROCE of -0.01%
- Auburn National Bancorp has ROCE of -0.01%
- Galaxy Digital has ROCE of -0.01%
- The Gap has ROCE of -0.01%
- Theratechnologies has ROCE of 0.00%
- Tejon Ranch Co has ROCE of 0.01%
- Glen Burnie Bancorp has ROCE of 0.02%
- MSP Steel & Power has ROCE of 0.02%
- TTL Beteiligungs- und Grundbesitz-AG has ROCE of 0.03%
- First Foundation Inc has ROCE of 0.03%
- FirstMark Horizon Acquisition has ROCE of 0.03%